COMPARATIVE INVIVO METABOLISM OF 6-[F-18]FLUORO-L-DOPA AND [H-3] L-DOPA IN RATS

被引:99
作者
MELEGA, WP
LUXEN, A
PERLMUTTER, MM
NISSENSON, CHK
PHELPS, ME
BARRIO, JR
机构
[1] UNIV CALIF LOS ANGELES,SCH MED,DEPT RADIOL SCI,DIV NUCL MED & BIOPHYS,LOS ANGELES,CA 90024
[2] UNIV CALIF LOS ANGELES,SCH MED,NUCL MED LAB,LOS ANGELES,CA 90024
[3] UNIV CALIF LOS ANGELES,SCH MED,DEPT PHARMACOL,LOS ANGELES,CA 90024
关键词
D O I
10.1016/0006-2952(90)90601-G
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In vivo double-label experiments in rats were designed to correlate the peripheral and cerebral metabolism of 6-[18F]fluoro-l-DOPA ([18F]FDOPA) with that of [3H]l-DOPA. Authentic samples of the major [18F]FDOPA metabolites were synthesized to identify the 18F-labeled metabolites. After carbidopa pretreatment and intravenous administration of the compound, the products of peripheral metabolism in plasma were analyzed at times from 3 to 60 min. In the periphery, amine conjugates were detected but they accounted for less than 15% of the total radioactivity; the major metabolites were 3-O-methyl-6-[18F]fluoro-l-DOPA and 3-O-methyl-[3H]l-DOPA. The rate and extent of 3-O-methylation of [18F]FDOPA exceeded that of [3H]l-DOPA. Both 3-O-methylated products entered the striatum and cerebellum where they contributed significant but uniform activity. Analysis of cerebral metabolism in these structures indicated a linear accumulation of total radioactivity: a striatum/cerebellum ratio of 2 was observed by 60 min. 6-[18F]Fluorodopamine (35%) and [3H]dopamine (55%) were the major metabolites formed in the striatum: however, the methylated [18F]FDOPA and [3H]DOPA products of predominantly peripheral origin represented 55% (18F) and 35% (3H) of the total radioactivity respectively. Other [3H]dopamine metabolites and their 18F-labeled analogs represented less than 10-15% at all times analyzed. The cerebellum radioactivity was composed only of [18F]FDOPA, [3H]DOPA and their 3-O-methylated products. These data will serve as the basis for the development of kinetic models of [18F]FDOPA metabolism that can be applied to the evaluation of central dopamine biochemistry with positron emission tomography in humans. © 1990.
引用
收藏
页码:1853 / 1860
页数:8
相关论文
共 38 条
[1]  
BARRIO JR, 1988, ANNU REV PHARMACOL, V28, P213
[2]  
BELBECK L, 1980, AM J PHYSIOL, V238, pR318
[3]   INHIBITION OF DOPA DECARBOXYLATION BY ANALOGS OF TRYPTOPHAN [J].
BOSIN, TR ;
BALDWIN, JR ;
MAICKEL, RP .
BIOCHEMICAL PHARMACOLOGY, 1978, 27 (08) :1289-1291
[4]  
BUTLER A, 1966, PHARMACOL REV, V18, P369
[5]  
CHIEUH CC, 1983, J PHARMACOL EXP THER, V225, P529
[6]   INFLUENCE OF FLUORINE SUBSTITUTION ON THE SITE OF ENZYMATIC O-METHYLATION OF FLUORINATED NOREPINEPHRINES [J].
CREVELING, CR ;
MCNEAL, ET ;
CANTACUZENE, D ;
KIRK, KL .
JOURNAL OF MEDICINAL CHEMISTRY, 1981, 24 (12) :1395-1399
[7]   THE EFFECT OF RING-FLUORINATION ON THE RATE OF O-METHYLATION OF DIHYDROXYPHENYLALANINE (DOPA) BY CATECHOL-O-METHYLTRANSFERASE - SIGNIFICANCE IN THE DEVELOPMENT OF F-18-PETT SCANNING AGENTS [J].
CREVELING, CR ;
KIRK, KL .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 130 (03) :1123-1131
[8]   KINETICS OF INVITRO DECARBOXYLATION AND THE INVIVO METABOLISM OF 2-F-18-FLUORODOPA AND 6-F-18-FLUORODOPA IN THE HOODED RAT [J].
CUMMING, P ;
HAUSSER, M ;
MARTIN, WRW ;
GRIERSON, J ;
ADAM, MJ ;
RUTH, TJ ;
MCGEER, EG .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (02) :247-250
[9]  
CUMMING P, 1987, J NEUROCHEM, V48, P601
[10]  
FIRNAU G, 1988, J NUCL MED, V29, P363